rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2011-7-5-613-619rpcardio-936Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯСHOICE OF ZOFENOPRIL AND HYDROCHLOROTHIAZIDE COMBINATION IN THE TREATMENT OF ARTERIAL HYPERTENSIONВЫБОР КОМБИНАЦИИ ЗОФЕНОПРИЛА И ГИДРОХЛОРОТИАЗИДА ПРИ ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИДжаианиН. А.DzhaianiN. A.

д.м.н., профессор кафедры скорой медицинской помощи

doctorni@yandex.ruМосковский Государственный медико-стоматологический университетРоссияMoscow State University of Medicine and DentistryRussian Federation20112101201675613619Copyright © Dzhaiani N.A., 20162016Джаиани Н.А.Dzhaiani N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/936

Problems of antihypertensive therapy are discussed in the light of the present epidemiological situation with arterial hypertension. ACE inhibitors have a special place among the antihypertensive drugs. Advantages and evidence base of ACE inhibitors representative — zofеnopril highlighted. Special attention is given to combined antihypertensive therapy , particularly combination of zofenopril and hydrochlorothiazide.

Рассматриваются вопросы антигипертензивной терапии с учетом настоящей эпидемиологической ситуации по артериальной гипертонии. Среди антигипертензивных препаратов особое место занимают ингибиторы АПФ. Обсуждаются преимущества и доказательная база представителя ингибиторов АПФ зофеноприла. Особое внимание уделяется комбинированной антигипертензивной терапии, в частности комбинации зофеноприла и гидрохлоротиазида.

артериальная гипертониякомбинированная терапиязофеноприлгидрохлоротиазидarterial hypertensioncombined therapyzofenoprilhydrochlorothiazideReferencesKearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data. The Lancet 2005; 365: 217-223.Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data. The Lancet 2005; 365: 217-223.Ageev F.T., Fomin I.V., Mareev V.Iu., Belenkov Iu.N. Prevalence of Arterial Hipertension in European Part of Russian Federation. Data From EPOCHA Study. Kardiologiia. 2004;44(11):50-4. Russian (Агеев Ф.Т., Фомин И.В., Мареев Ю.В. и др. Распространенность артериальной гипертонии в европейской части Российской Федерации. Данные исследования ЭПОХА. Кардиология 2004;11:50–53).Ageev F.T., Fomin I.V., Mareev V.Iu., Belenkov Iu.N. Prevalence of Arterial Hipertension in European Part of Russian Federation. Data From EPOCHA Study. Kardiologiia. 2004;44(11):50-4. Russian (Агеев Ф.Т., Фомин И.В., Мареев Ю.В. и др. Распространенность артериальной гипертонии в европейской части Российской Федерации. Данные исследования ЭПОХА. Кардиология 2004;11:50–53).Shkolnikov V. et al. Changes in life expectancy in Russia in the mid-1900s. Lancet 2001; 357: 917–21.Shkolnikov V. et al. Changes in life expectancy in Russia in the mid-1900s. Lancet 2001; 357: 917–21.Moser M., Herbert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214-1218.Moser M., Herbert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214-1218.Herbert P.R., Moser M., Mayer J. et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578-581.Herbert P.R., Moser M., Mayer J. et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578-581.National guidelines for diagnosis and treatment of hypertension. The Assembly of Experts SCRF, RM-SAH. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7 (6) suppl 2: 1-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Совет экспертов ВНОК, РМО-АГ. Кардиоваскулярная терапия и профилактика 2008; 7 (6) приложение 2: 1-32).National guidelines for diagnosis and treatment of hypertension. The Assembly of Experts SCRF, RM-SAH. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7 (6) suppl 2: 1-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Совет экспертов ВНОК, РМО-АГ. Кардиоваскулярная терапия и профилактика 2008; 7 (6) приложение 2: 1-32).Lewington S., Clarke R., Qizilbash N. et al. Prospective Studies Collaboration. Agespecific relevance of usual blood pressure to vascular mortality: a meta–analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.Lewington S., Clarke R., Qizilbash N. et al. Prospective Studies Collaboration. Agespecific relevance of usual blood pressure to vascular mortality: a meta–analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.Karpov Iu.A. Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy. Kardiologiia 2005;45(12):87-92. Russian (Карпов Ю.А. Ишемическая болезнь сердца в сочетании с артериальной гипертонией: особенности течения и выбор терапии. Кардиология 2005; 12: 93–98).Karpov Iu.A. Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy. Kardiologiia 2005;45(12):87-92. Russian (Карпов Ю.А. Ишемическая болезнь сердца в сочетании с артериальной гипертонией: особенности течения и выбор терапии. Кардиология 2005; 12: 93–98).ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high–risk hypertensive patients randomized to angiotensin–converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981–2997.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high–risk hypertensive patients randomized to angiotensin–converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid–Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981–2997.Pepine C.J., Handberg E.M., Cooper–DeHoff R.M. et al.; INVEST Investigators. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003; 290(21): 2805–2816.Pepine C.J., Handberg E.M., Cooper–DeHoff R.M. et al.; INVEST Investigators. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003; 290(21): 2805–2816.Dahlof B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906.Dahlof B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906.Zhitnikova L.M. Combination therapy of hypertension: an efficient and convenient. Russkiy meditsinskiy zhurnal 2011; 19(4): 180–185. Russian (Житникова Л.М. Комбинированная терапия артериальной гипертонии: эффективно и удобно. Русский медицинский журнал 2011; 19(4): 180–185).Zhitnikova L.M. Combination therapy of hypertension: an efficient and convenient. Russkiy meditsinskiy zhurnal 2011; 19(4): 180–185. Russian (Житникова Л.М. Комбинированная терапия артериальной гипертонии: эффективно и удобно. Русский медицинский журнал 2011; 19(4): 180–185).Karpov Yu.A. New guidelines for hypertension RMOAG / GFCF in 2010: issues of combination therapy. Russkiy meditsinskiy zhurnal 2010; 22: 1290. Russian (Карпов Ю.А. Новые рекомендации по артериальной гипертензии РМОАГ/ВНОК 2010 г.: вопросы комбинированной терапии. Русский медицинский журнал 2010; 22: 1290).Karpov Yu.A. New guidelines for hypertension RMOAG / GFCF in 2010: issues of combination therapy. Russkiy meditsinskiy zhurnal 2010; 22: 1290. Russian (Карпов Ю.А. Новые рекомендации по артериальной гипертензии РМОАГ/ВНОК 2010 г.: вопросы комбинированной терапии. Русский медицинский журнал 2010; 22: 1290).Marzo A., Dal Bo L., Mazzucchelli P. et al. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Arzneimittelforschung 2002;52(4):233–42.Marzo A., Dal Bo L., Mazzucchelli P. et al. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Arzneimittelforschung 2002;52(4):233–42.Morrison R.A., Burkett D.E., Arnold M.E. et al. Sites of first–pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs. Pharm Res 1991;8(3):370–5.Morrison R.A., Burkett D.E., Arnold M.E. et al. Sites of first–pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs. Pharm Res 1991;8(3):370–5.Ranadive S.A., Chen A.X., Serajuddin A.T. Relative lipophilicities and structural–pharmacological considerations of various angiotensin–converting enzyme (ACE) inhibitors. Pharm Res 1992;9(11): 1480–6.Ranadive S.A., Chen A.X., Serajuddin A.T. Relative lipophilicities and structural–pharmacological considerations of various angiotensin–converting enzyme (ACE) inhibitors. Pharm Res 1992;9(11): 1480–6.Singhvi S.M., Foley J.E., Willard D.A., Morrison R.A. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990;79(11):970–3.Singhvi S.M., Foley J.E., Willard D.A., Morrison R.A. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990;79(11):970–3.Marzo A., Dal Bo L., Mazzucchelli P. et al. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittelforschung 1999;49(12):992–6.Marzo A., Dal Bo L., Mazzucchelli P. et al. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittelforschung 1999;49(12):992–6.Singhvi S.M., Foley J.E., Willard D.A., Morrison R.A. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990;79(11):970–3.Singhvi S.M., Foley J.E., Willard D.A., Morrison R.A. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990;79(11):970–3.Malacco E., Piazza S., Omboni S. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double–Blind, Multicentre Study. Clin Drug Investig 2005;25(3):175–182.Malacco E., Piazza S., Omboni S. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double–Blind, Multicentre Study. Clin Drug Investig 2005;25(3):175–182.Subissi A., Evangelista S., Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999;17 (2); 115-133.Subissi A., Evangelista S., Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999;17 (2); 115-133.Tio R., de Langen C., de Graef P. et al. The effects of oral pretreatment with zofenopril, an angiotensin converting enzyme inhibitor, on early reperfusion and subseguent electrophysiologic stability in the pig. Cardiovasc Drugs Ther 1990;4 (31):695-703.Tio R., de Langen C., de Graef P. et al. The effects of oral pretreatment with zofenopril, an angiotensin converting enzyme inhibitor, on early reperfusion and subseguent electrophysiologic stability in the pig. Cardiovasc Drugs Ther 1990;4 (31):695-703.Preobrazhenskiy D.V., Sidorenko B.A., Skavronskaya T.V., et al. zofenopril — cardioprotective angiotensin-converting enzyme inhibitors: clinical pharmacology and experience with the treatment of hypertension. Rossiyskiy kardiologicheskiy zhurnal 2006; 1: 87–94. Russian (Преображенский Д.В., Сидоренко Б.А., Скавронская Т.В. и др. В. Зофеноприл — кардиопротективный ингибитор ангиотензин– превращающего фермента: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Российский кардиологический журнал 2006; 1: 87–94).Preobrazhenskiy D.V., Sidorenko B.A., Skavronskaya T.V., et al. zofenopril — cardioprotective angiotensin-converting enzyme inhibitors: clinical pharmacology and experience with the treatment of hypertension. Rossiyskiy kardiologicheskiy zhurnal 2006; 1: 87–94. Russian (Преображенский Д.В., Сидоренко Б.А., Скавронская Т.В. и др. В. Зофеноприл — кардиопротективный ингибитор ангиотензин– превращающего фермента: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Российский кардиологический журнал 2006; 1: 87–94).Preobrazhenskiy D.V., Sidorenko B.A., Skavronskaya T.V. et al. zofenopril — cardioprotective angiotensin-converting enzyme inhibitors: clinical pharmacology and experience with the treatment of hypertension. Rossiyskiy kardiologicheskiy zhurnal 2006; 1: 87–94. Russian (Преображенский Д.В., Сидорен-ко Б.А., Скавронская Т.В. и др. В. Зофеноприл — кардиопротективный ингибитор ангиотензин– превращающего фермента: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Российский кардиологический журнал 2006; 1: 87–94).Preobrazhenskiy D.V., Sidorenko B.A., Skavronskaya T.V. et al. zofenopril — cardioprotective angiotensin-converting enzyme inhibitors: clinical pharmacology and experience with the treatment of hypertension. Rossiyskiy kardiologicheskiy zhurnal 2006; 1: 87–94. Russian (Преображенский Д.В., Сидорен-ко Б.А., Скавронская Т.В. и др. В. Зофеноприл — кардиопротективный ингибитор ангиотензин– превращающего фермента: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Российский кардиологический журнал 2006; 1: 87–94).Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332 (2):80-85.Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995;332 (2):80-85.Borghi C., Bacchelli S., Degli Espositi D. et al. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevalion acute anterior myocardial infarction. Am Heart J 2006;152Borghi C., Bacchelli S., Degli Espositi D. et al. Effects of early angiotensin-converting enzyme inhibition in patients with non-ST-elevalion acute anterior myocardial infarction. Am Heart J 2006;152Borghi C., Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction. Results of the Survival ofMyocardial Infarction Long-Term Evaluation-2 (SMILE-2) study. Am Heart J 2003;145 (1):80-87.Borghi C., Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction. Results of the Survival ofMyocardial Infarction Long-Term Evaluation-2 (SMILE-2) study. Am Heart J 2003;145 (1):80-87.Borghi C., Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Am Heart J 2007;153(3):445.e7-14.Borghi C., Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Am Heart J 2007;153(3):445.e7-14.Borghi C., Bacchelli S., Degli Espositi D. et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 1999;12 (7):665-672.Borghi C., Bacchelli S., Degli Espositi D. et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 1999;12 (7):665-672.Malacco E., Giusti A., on behalf of the Zofenopril Study Group. Once–daily zofenopril provides 24– hour ambulatory blood pressures control in hypertensive patients aged under 65 years. Am J Hypertens 1998; 11 (4 part 2): 70.Malacco E., Giusti A., on behalf of the Zofenopril Study Group. Once–daily zofenopril provides 24– hour ambulatory blood pressures control in hypertensive patients aged under 65 years. Am J Hypertens 1998; 11 (4 part 2): 70.Malacco E., Castiglioni G., Corradi L. et al. Dose–response relationship of zofenopril in essential hypertension. Clin Drug Invest 2002; 22 (1): 9–15.Malacco E., Castiglioni G., Corradi L. et al. Dose–response relationship of zofenopril in essential hypertension. Clin Drug Invest 2002; 22 (1): 9–15.Lacourciere Y., Provencher P. Comparative effects of zofenopril and hydrochlorthiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Brit J Clin Pharmacol 1989; 2 (11): 861–864.Lacourciere Y., Provencher P. Comparative effects of zofenopril and hydrochlorthiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Brit J Clin Pharmacol 1989; 2 (11): 861–864.Giusti A., Bertolotti M., Llabres S. et al. Comparison of the efficacy of zofenopril or enalapril in patients with mild to moderate hypertension. Am J Hypertens 1999; 12 (4 part 2): 28.Giusti A., Bertolotti M., Llabres S. et al. Comparison of the efficacy of zofenopril or enalapril in patients with mild to moderate hypertension. Am J Hypertens 1999; 12 (4 part 2): 28.Giusti A., Bertolotti M., Clark W. I. C. et al. The efficacy and safety of zofenopril compared to amlodipine in patients with mild to moderate hypertension. Am J Hypertens 1999; 12 (4 part 2): 140.Giusti A., Bertolotti M., Clark W. I. C. et al. The efficacy and safety of zofenopril compared to amlodipine in patients with mild to moderate hypertension. Am J Hypertens 1999; 12 (4 part 2): 140.Borghi C., Bacchelli S., Esposti D.D., Ambrosioni E. A review of the angiotensin converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opinion on Pharmacotherapy 2004; 5 (9): 1965–1977.Borghi C., Bacchelli S., Esposti D.D., Ambrosioni E. A review of the angiotensin converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opinion on Pharmacotherapy 2004; 5 (9): 1965–1977.Dzhaiani N.A., Zhirov I.V. Combined antihypertensive drug therapy: what can we do to control blood pressure. Russkiy meditsinskiy zhurnal 2005; 13(11): 741–747. Russian (Джаиани Н.А., Жиров И.В. Комбинированная антигипертензивная фармакотерапия: что мы можем сделать для контроля артериального давления. Русский медицинский журнал 2005; 13(11): 741–747).Dzhaiani N.A., Zhirov I.V. Combined antihypertensive drug therapy: what can we do to control blood pressure. Russkiy meditsinskiy zhurnal 2005; 13(11): 741–747. Russian (Джаиани Н.А., Жиров И.В. Комбинированная антигипертензивная фармакотерапия: что мы можем сделать для контроля артериального давления. Русский медицинский журнал 2005; 13(11): 741–747).Parati G., Omboni S., Malacco E. Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure. Blood Pressure 2006; 15(Suppl 1): 7–17.Parati G., Omboni S., Malacco E. Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure. Blood Pressure 2006; 15(Suppl 1): 7–17.Malacco E., Omboni S. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrom. Advances in therapy 2007; 24: 1006-1015.Malacco E., Omboni S. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrom. Advances in therapy 2007; 24: 1006-1015.

The authors declare that there are no conflicts of interest present.